

# MAKE HAY WHILE THE SUN SHINES

Q4 2024

## Overview

Despite a better backdrop of falling inflation, falling interest rates and rising public markets, the private equity industry remained subdued in 2024. Investment activity and exits fell for the fourth successive year, while lower fundraising volumes were only propped up by a relatively small number of mega cap funds. Clearly, investors remain liquidity constrained and are unable to commit material amounts to new funds. On the other hand, the secondaries market had a very strong year, showing over 40% growth in transaction volume on the back of strong demand from investors. Another area of growth has been open-ended 'evergreen' funds, which allow investors to redeem at a time of their choosing: a trend driven by increasing demand for private equity exposure from a broader range of investors and perhaps the promise of more control over liquidity.

Looking ahead, 2025 has all the ingredients necessary for a better year: valuations remain at a significant discount to public markets, credit conditions have improved and compelling investment opportunities are arising across multiple sectors. Where should investors focus? Read on for our views!

### Secondaries: the bright spark

Private equity investment activity in 2024 was down 16% on 2023, at USD 663bn<sup>1</sup>. This was mainly driven by falls in Europe (-22%) and APAC (-52%), while North America was marginally up (+6%).

Exit activity also fell in 2024, by 12% to USD 392bn. This was driven by North America (-3%), Europe (-31%) and APAC (-13%)<sup>2</sup>.

These declines cannot be taken in isolation. Since the peak in 2021, investment and exit activity have fallen 35% and 50% respectively and are now at levels last seen in 2017/2018. However, this doesn't tell the whole story. Since 2017, dry powder has almost doubled while aggregate NAV has almost tripled. Thus, relative investment and exit activity are actually at the lowest for well over a decade.

Meanwhile, fundraising in 2024 was also down vs. the prior year. In 2024, USD 378bn was raised globally for buyout funds, 22% lower than 2022. However, similar to 2023, the 15 largest funds accounted for over 45% of the total<sup>3</sup>.

The only part of the market demonstrating positive growth was secondaries. Investment volume for secondaries registered a record USD 152bn in 2024 - a staggering 41% higher than 2023<sup>4</sup>. This spectacular growth was caused by a perfect storm of record fundraising, combined with investors motivated to sell due to low



**Paul Newsome**  
Head of Investment Solutions,  
Private Equity

### Key Points

1. 2025 is likely to be a better year for private equity
2. Our exit pace continues to buck the market trend
3. Secondaries will continue to move towards being a core holding while the popularity of open-ended funds will grow

<sup>1</sup> Preqin, as at January 2025

<sup>2</sup> Ibid

<sup>3</sup> Ibid

<sup>4</sup> Lazard Secondary Market Report, January 2025

Read more of our latest investment thinking online: [www.unigestion.com/insights](http://www.unigestion.com/insights)



distributions and overallocation and, at the same time, GPs motivated to pursue GP-leds in order to generate distributions and keep hold of “trophy assets”.

## Unigestion exits: bucking the trend

In 2024, we enjoyed another strong year for exits, distributing over USD 1bn back to investors, over 30% more than the amount we invested. During the last three years, we have distributed over USD 3bn back to our investors, highlighting the effectiveness of our strategy of targeting mid-market leaders.

Key highlights in Q4 2024 include our exits from Stingray (from our secondaries programs) and Kindred (from our direct programs). We invested in Stingray in 2020 through a multi-asset continuation vehicle. Stingray, based in Norway, utilises a combination of camera vision, advanced proprietary software, and laser technology to remove sea lice from fish in a humane and efficient manner. This system not only improves fish health and welfare but also enhances operational efficiency for fish farmers by reducing the need for manual handling of the fish and the associated mortality. It also reduces the need to use chemicals which can be damaging to the environment. The company was acquired by Novo Holdings, resulting in attractive proceeds for our secondaries programs.

At the end of the year, we sold Kindred to Livingbridge, a UK mid-market private equity firm. Under the ownership of the Unigestion Direct Opportunity's fund, Kindred has become one of the UK's largest nursery groups, increasing its platform from four to 48 sites. The company has also established robust processes that ensure the sites acquired by Kindred are of exceptional quality and can be seamlessly integrated, leveraging the group's finance, marketing and HR functions. Given the continued positive outlook for Kindred, not least the exceptional management team headed by CEO Ruth Pimental, Unigestion will continue to support the company alongside Livingbridge with a new investment.

We also sold two of our portfolio companies in Unigestion Direct II - our 2020 vintage fund. HTBA and Aquam Water Services were both acquired during, or just before, the COVID pandemic. Given the strength of their respective offerings, leadership in their sectors and the resilient growth achieved, both companies attracted multiple buyers and were ultimately sold for attractive prices. More detail on these companies is provided later in this report.

In the second half of 2024, we held final closes for Unigestion Direct III and Unigestion Climate Impact. Both portfolios were well invested by the time of their final closes and marked up above cost, attracting a flurry of new investors. We continue to see attractive dealflow for both programs.

In November, for example, we closed a direct investment in US-headquartered Odyssey Behavioural Healthcare. This company operates 63 behavioural health facilities across 10 states, treating mental health, eating disorders, and substance use disorders. This company has enjoyed strong, sustainable growth, driven by increased penetration given the continued de-stigmatisation around seeking treatment - as well as its numerous robust payor relationships. The company plans to continue growing by rolling out its facilities into adjacent states.

Meanwhile, we continue to fundraise for our latest secondaries strategy. The portfolio is already well invested, with over 30% of the target fund size committed to 13 transactions. These deals provide an excellent representation of our strategy: (1) five of the deals are LP stake transactions in single funds with early distributions expected, (2) five are GP-led deals with high target multiples and early liquidity expected in several cases, (3) three are mid-life direct secondaries, where we pay no fee and carry and; (4) ten of the 13 deals have come from existing GP relationships. Taken together, this demonstrates our ability to design a portfolio that can generate early liquidity, an optimal max cash out of pocket and a high cash-on-cash multiple with no leverage. The portfolio currently has an attractive gross multiple, increasing its appeal to new investors.

Read more of our latest investment thinking online: [www.unigestion.com/insights](http://www.unigestion.com/insights)



Finally, completing a busy year for Unigestion, we launched our latest Emerging Manager Choice (EMC) strategy. Building on our three-decade track record of backing future stars, this program will commit to between 12 and 15 first or second funds of “emerging”, specialist managers, with a 30% allocation to direct investments.

EMC I (a 2018 vintage) demonstrates the returns available from emerging managers, delivering top quartile returns when benchmarked against all buyout funds<sup>5</sup>. We will discuss this strategy in more detail in our next quarterly letter.

## Our private equity outlook for 2025

---

Many market participants were hoping that 2024 would mark a turnaround for the private equity market, given better macro conditions and the expectation that the pressure of more dry powder and unrealised value would cause the dam to burst. This did not come to pass.

Nevertheless, our 2024 predictions were mostly accurate.

First, although we distributed more to our investors in 2024 than in 2023, we were wrong to say that exit activity would improve overall. However, we were correct to predict that there would be a high number of broken auction processes. In April 2024, Investec reported that 66% of GPs surveyed had seen more broken auction processes in the previous year than the preceding 12 months<sup>6</sup>.

Second, we were correct that GP-led continuation funds will be the main driver behind growth in the secondary market. The overall secondary market had its strongest ever year in 2024, with USD 152bn of secondary volume. A record USD 72bn of this came from GP-led transactions<sup>7</sup>.

Third, mid-market returns were not materially stronger than large cap returns, but still held up well considering that large cap returns tend to be more correlated to public markets. In 2024, mid-market net annual returns were on average 8% - certainly higher than large caps (0%) but the same as mega cap (8%)<sup>8</sup>. Meanwhile, the MSCI World Index delivered 34% over the same period.

Fourth, we predicted that the main investment topics in 2024 would be reshoring, healthcare innovation and education services. While it is not clear if reshoring, in particular was a driver, there was certainly an uptick in deals in manufacturing, healthtech and edtech, against a general decline in investment activity<sup>9</sup>.

We know that we are not alone in handing out market outlooks. Nonetheless, we hope that our 2025 outlook provides some assistance in helping you assess short and long-term trends in the market.

**The secondaries market continues to grow, as investors move it from a satellite to a core allocation.** Investors have historically maintained a 2%-10% allocation to secondaries as part of their overall private equity exposure in order to benefit from J-curve mitigation, diversification and the shorter cash cycles that have traditionally been the hallmark of secondaries. Now that GP-led deals have firmly established themselves as a key component of the mix, the overall profile of secondaries has changed. Today, secondaries also bring comparable TVPIs and IRRs to buyout funds, high cash-on-cash multiples and high-quality assets (from the “trophy asset” GP-led deals). Consequently, we expect that many investors will begin increasing their allocation into more the 10% – 50% range, as evidenced by an uptick in secondaries fundraising.

---

<sup>5</sup> Source: Preqin. Based on a Preqin peer group of funds using the most recent data available. Care should be taken with rankings data considering Preqin represents a relatively small subset of private equity investments

<sup>6</sup> Investec, April 2024

<sup>7</sup> Lazard Secondary Market Report, January 2025

<sup>8</sup> Preqin, January 2025 (performance for the 12 months to 30 September 2024)

<sup>9</sup> Preqin, January 2024

Read more of our latest investment thinking online: [www.unigestion.com/insights](http://www.unigestion.com/insights)



### **Investors begin to pivot towards Europe as North America becomes too expensive.**

In 2024, 63% of global investment activity occurred in North America - a ten year high. Meanwhile, the median US buyout EV to EBITDA multiple was a record high of 15.6x vs. 12.8x in Europe. In the short and medium term, we expect increasing productivity and further deregulation to unlock growth and investment opportunities. European governments have realised that sectors such as energy transition cannot be solved without private capital. With future growth and margin improvement already priced into North American valuations, investors will now look to Europe for undervalued investment opportunities.

**There will be a surge in private equity open-ended fund launches.** While many of the larger private equity firms have already launched their own open-ended funds, we think this is still only scratching the surface. The retail and private wealth market is huge, representing around 50% of all capital invested in public stock. However, in private assets, retail and private wealth still only represents around 10% of committed capital. Open-ended funds, with lower minimum investment sizes, instant exposure and monthly or quarterly liquidity are ideal for such investors. In addition, institutional investors are increasingly adding such funds to their investment mix, enticed by the more predictable liquidity - especially in the current environment where distributions are sparse.

**The key investment topics for 2025 will be government efficiency, energy transformation, reshoring and healthcare efficiency.** With government budgets being trimmed and whole departments being cut, efficiency will be the name of the game. This will lead to opportunities around software and tech-enabled services. Meanwhile, renewable energy has become so much cheaper than traditional power generation, that the energy mix is changing at a breakneck speed. However, this creates demand for smart grid technology, energy infrastructure and related services. We also believe that, as in 2024, reshoring will remain a key focus for many companies, especially in the US. Finally, with healthcare systems at breaking point in many countries, the application of AI and other tech-enabled solutions will provide ample investment opportunities. We believe that there will be a notable uptick in dealflow in all of these sectors, especially in the mid-market.

While we remain optimistic about the coming year, we are cautious about the various political risks present in many regions. In the US, it is unclear what effect the incoming administration's new policies will have on investment opportunities, especially if inflation were to increase again. Equally, in Europe, Germany and France have their own political problems, while the war in Ukraine continues on Europe's doorstep and increases pressure on governments to commit more cash to defence budgets.

Whatever happens, we are confident that, if we remain diligent and true to our convictions, we will continue to uncover attractive opportunities for our investors. We are excited to embark on another year of sourcing the very best deals and delivering attractive exits.

## **Unigestion Private Equity Activity**

---

Here are the highlights of some of the investments that we completed in Q4:



In October, Unigestion closed a single-asset continuation fund consisting of CES Power alongside Allied Industrial Partners. CES Power is a leading provider of essential infrastructure to live events such as sports broadcast and non-broadcast, festivals & concerts, film and TV across US and Europe. The company provides a wide range of power- and networking-focused services including power generation & distribution, temperature control,

Read more of our latest investment thinking online: [www.unigestion.com/insights](http://www.unigestion.com/insights)



networking, CCTV, mapping & CAD services, ramps & matting, and turnkey project management. CES Power is one of the few providers with the geographic footprint, fleet size, and service expertise to serve customers' largest and most complex live events across US and Europe. The company has become the stand-out pure-play clear category leader in events. CES Power addresses a market of USD 15bn, which is expected to grow at 7% through 2028..



In the same month, Stingray Marine Solutions, a portfolio company in Euro Choice Secondary II and Unigestion Secondary Opportunity IV, was sold to Novo Holdings. Stingray Marine Solutions, founded in 2012 and headquartered in Oslo, Norway, specialises in intelligent aquaculture technology aimed at increasing sustainable salmon production. The company's product, the Stingray system, utilises a combination of camera vision, advanced proprietary software, and laser technology to remove sea lice from fish in a humane and efficient manner. This system not only improves fish health and welfare but also enhances operational efficiency for fish farmers by reducing the need for manual handling of the fish and the associated mortality.



Unigestion also completed the acquisition of an LP interest in Longreach 3 during October. The transaction was part of a larger portfolio sale, where the secondary investment team of Unigestion managed to carve out this single line at a discount of 20%. Longreach 3 has a focus on mid-market buyout investments in Japan, with the view to capturing Asian and global growth opportunities. The fund's concentrated portfolio consists of five well performing buyout positions with healthy growth of over 20% across the portfolio. The portfolio is well-diversified across sectors such as industrials, consumer and business services and should provide near-term liquidity.



In October as well, Xenon Private Equity together with Unigestion, exited Tecnopool. Tecnopool is a leading manufacturer of equipment and production lines for food processing, especially industrial and artisanal baking. The company specialises in providing advanced equipment such as ovens, mixers, freezers and spiral conveyor systems for a broad range of applications in baking and other food segments. Tecnopool's solutions are used by major food producers globally, supporting efficient, high-quality production.



In November, Riverside - together with Unigestion - sold HealthTech BioActives (HTBA) to Miura Partners. HTBA is a Spain-based, a science-based company specialising in the production and commercialisation of natural ingredients, such as citrus flavonoids, and Europe's leading provider of active vitamin B12 forms for the pharmaceutical, nutraceutical, food and beverage, and animal nutrition sectors. During our ownership, the company's manufacturing capacity has been significantly increased, the international distribution widened and the firm's R&D capabilities enhanced.



Also in November, Unigestion completed a direct secondary transaction in Fokus Nordic, alongside BlackFin, in order to acquire real estate firm DEAS Asset Management. Fokus Nordic is a leading real estate asset manager in the Nordics with more than EUR 5bn in AUM pre-transaction. It provides a wide range of services for real estate investors, e.g. preparation of business plans, controlling, finance and reporting, for a variety of property

Read more of our latest investment thinking online: [www.unigestion.com/insights](http://www.unigestion.com/insights)



segments, such as residential and commercial. Its customers are mainly larger real estate investors, including pension funds but also international investment firms like Blackstone, Invesco and Union Investment. Through the acquisition of DEAS Asset Management, Fokus Nordic has reached the scale to serve global real estate investors seeking Nordic exposure with core, core+, value-add and opportunistic strategies, while maintaining the highest standards of service for current clients. The combination of Fokus Nordic and DEAS Asset Management creates a unique Nordic 'platform' with approx. 170 employees operating in four countries and with a total AuM of c. EUR 10bn. The acquisition will accelerate the growth of Fokus Nordic and immediately position the company to become one of the leading real estate asset and investment managers in the Nordics.



In the same month, Unigestion closed a direct investment into US-headquartered Odyssey Behavioral Healthcare alongside JLL Partners. Odyssey Behavioral Healthcare operates 63 behavioural health facilities across 10 states. Its treatment model encompasses Residential Treatment Centers ("RTC") with 60-day lengths of stay, as well as outpatient clinics offering Partial Hospitalisation Programs ("PHP") and Intensive Outpatient Programs ("IOP") that often treat clients for longer periods of time at lower levels of care. The business focuses on mental health, eating disorders, and substance use disorder treatment, and has a reputation for providing quality care while maintaining numerous robust payor relationships.



Also in November, Unigestion sold its investment in Aquam Water Services (AWS) to Indicor. AWS is the UK's number one provider of outsourced standpipe management services to water utilities, with a core offering of managing the rental process for end-users of standpipes, and providing various services to water utilities, including end-user billing and reporting / detecting illegal end-user standpipe use. During our ownership, the company has transitioned from a UK-centric old economy business with defensive cash-flows into an international, new economy, growth IoT business. AWS's understanding of customer needs in the UK utility market and its measurement of increasingly valuable network data position it well to provide sensors and data on other parts of the 'last mile' network. Alongside significant EBITDA progress during the holding period and visibility of growth in existing and new contracts, a private equity-backed trade buyer expressed inbound interest resulting in a strong exit ahead of the original planned timeline.



In the same month, sold its investment in nurseries group Kindred to Livingbridge. Kindred is one of the UK's most distinguished providers of early years education for children aged 0-5, providing exceptional, professional childcare and early years education across Southern England and the Midlands. Unigestion invested in Kindred in 2017 supporting the company's strategy with a targeted programme of investment that has helped steer the company from four nurseries to 48 locations today. Unigestion has supported the establishment of robust processes that ensure the sites acquired by Kindred are of exceptional quality and can be seamlessly integrated leveraging the group's finance, marketing and HR functions. The team instilled a focus on quality and a 'cluster-based model' that ensures each child receives high quality childcare across all locations. Given the continued positive outlook for Kindred, Unigestion will continue to support the Company alongside Livingbridge with a new investment.

---

Read more of our latest investment thinking online: [www.unigestion.com/insights](http://www.unigestion.com/insights)



In December, Unigestion completed an investment in PX3 Partners Fund I. PX3, a London-based fund manager, is a spin-out emerging manager founded in 2021 by three former partners at Rhône Group. The team aims to replicate its proven strategy of investing in pan-European mid-market buyouts. PX3 focuses on attractive subsectors within three core industries: Industrials, Business Services and Consumer, with a particular emphasis on corporate carve-outs and transatlantic investments. The manager is targeting a fund of €500m, to be deployed across eight investments, three of which have already been completed.

---

## CONTACT US

---

 | [unigestion.com](https://www.unigestion.com)

General Information [info@unigestion.com](mailto:info@unigestion.com)

Clients [clients@unigestion.com](mailto:clients@unigestion.com)

Press [pressrelations@unigestion.com](mailto:pressrelations@unigestion.com)

Read more of our latest investment thinking online: [www.unigestion.com/insights](https://www.unigestion.com/insights)

FOR QUALIFIED INSTITUTIONAL BUYERS, PROFESSIONAL AND INSTITUTIONAL INVESTORS ONLY. NOT FOR USE BY RETAIL CLIENTS



## Important Information

---

### INFORMATION ONLY FOR YOU

This document has been prepared for your information only and must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person without the prior written consent of Unigestion. It is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of, or domiciled or located in, any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.

### RELIANCE ON UNIGESTION

There is no guarantee that Unigestion will be successful in achieving any investment objectives. An investment strategy contains risks, including the risk of complete loss.

Except where otherwise specifically noted, the information contained herein, including performance data and assets under management, relates to the entire affiliated group of Unigestion entities over time. Such information is intended to provide you with background regarding the services, investment strategies and personnel of the Unigestion entities. No guarantee is made that all or any of the individuals involved in generating the performance on behalf of one or more Unigestion entities will be involved in managing any specific client account on behalf of another Unigestion entity.

### NOT A RECOMMENDATION OR OFFER

This is a promotional statement of our investment philosophy and services only in relation to the subject matter of this presentation. It constitutes neither investment advice nor recommendation. This document represents no offer, solicitation or suggestion of suitability to subscribe in either the investment vehicles to which it refers or to any securities or financial instruments described herein. Any such offer to sell or solicitation of an offer to purchase shall be made only by formal offering documents, which include, among others, a confidential offering memorandum, limited partnership agreement (if applicable), investment management agreement (if applicable), operating agreement (if applicable), and related subscription documents (if applicable). Such documentation contains additional information material to any decision to invest. Please contact your professional adviser/consultant before making an investment decision.

Reference to specific securities should not be construed as a recommendation to buy or sell such securities and is included for illustration purposes only.

### RISKS

Where possible we aim to disclose the material risks pertinent to this document. The views expressed in this document do not purport to be a complete description of the securities, markets and developments referred to in it. Unigestion maintains the right to delete or modify information without prior notice. The risk management practices and methods described herein are for illustrative purposes only and are subject to modification.

Investors shall conduct their own analysis of the risks (including any legal, regulatory, tax or other consequences) associated with an investment and should seek independent professional advice. Some of the investment strategies or financial instruments described or alluded to herein may be construed as high risk and not readily realisable investments, and may experience substantial & sudden losses including total loss of investment. These are not suitable for all types of investors. Unigestion has the ability in its sole discretion to change the strategies described herein.

### PAST PERFORMANCE

Past performance is not a reliable indicator of future results, the value of investments, can fall as well as rise, and there is no guarantee that your initial investment will be returned.

If performance is shown gross of management fees, you should be aware that the inclusion of fees, costs and charges will reduce investment returns.

Returns may increase or decrease as a result of currency fluctuations.

### NO INDEPENDENT VERIFICATION OR REPRESENTATION

No separate verification has been made as to the accuracy or completeness of the information herein. Data and graphical information herein are for information only and may have been derived from third party sources. Unigestion takes reasonable steps to verify, but does not guarantee, the accuracy and completeness of information from third party sources. As a result, no representation or warranty, expressed or implied, is or will be made by Unigestion in this respect and no responsibility or liability is or will be accepted. All information provided here is subject to change without notice. It should only be considered current as of the date of publication without regard to the date on which you may access the information. An investment with Unigestion, like all investments, contains risks, including total loss for the investor.

### TARGET RETURNS

Targeted returns reflect subjective determinations by Unigestion based on a variety of factors, including, among others, internal modeling, investment strategy, prior performance of similar products (if any), volatility measures, risk tolerance and market conditions. Target returns and/or forecasts are based on Unigestion's analytics including upside, base and downside scenarios and might include, but are not limited to, criteria and assumptions such as macro environment, enterprise value, turnover, EBITDA, debt, financial multiples and cash flows. Targeted returns are not intended to be actual performance and should not be relied upon as an indication of actual or future performance.

If target returns, forecasts or projections are shown gross of management fees, the inclusion of fees, costs and charges will reduce such numbers.

### USE OF INDICES

Information about any indices shown herein is provided to allow for comparison of the performance of the strategy to that of certain well-known and widely recognized indices. There is no representation that such index is an appropriate benchmark for such comparison. You cannot invest directly in an index and the indices represented do not take into account trading commissions and/or other brokerage or custodial costs. The volatility of the indices may be materially different from that of the strategy. In addition, the strategy's holdings may differ substantially from the securities that comprise the indices shown.

### HYPOTHETICAL, BACKTESTED OR SIMULATED PERFORMANCE

Hypothetical, backtested or simulated performance is not an indicator of future actual results and has many inherent limitations. The results reflect performance of a strategy not currently offered to any investor and do not represent returns that any investor actually attained. One of the limitations of hypothetical performance results is that they are generally prepared with the benefit of hindsight.

Read more of our latest investment thinking online: [www.unigestion.com/insights](http://www.unigestion.com/insights)





Hypothetical performance may use, among other factors, historical financials (turnover, EBITDA, debt, financial multiples), historical valuations, macro variables and fund manager variables. Hypothetical results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Changes in these assumptions may have a material impact on the hypothetical (backtested/simulated) returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions.

This information is provided for illustrative purposes only. Specifically, hypothetical (backtested/simulated) results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk in actual trading. For example, the ability to withstand losses or to adhere to a particular trading program in spite of trading losses are material points which can also adversely affect actual trading results. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized.

If hypothetical, backtested or simulated performance is shown gross of management fees, the inclusion of fees, costs and charges will reduce such numbers.

#### **ASSESSMENTS**

Unigestion may, based on its internal analysis, make assessments of a company's future potential as a market leader or other success. There is no guarantee that this will be realised.

## **Legal Entities Disseminating This Document**

---

#### **UNITED KINGDOM**

This material is disseminated in the United Kingdom by Unigestion (UK) Ltd., which is authorized and regulated by the Financial Conduct Authority ("FCA"). This information is intended only for professional clients and eligible counterparties, as defined in MiFID directive and has therefore not been adapted to retail clients.

#### **UNITED STATES**

In the United States, Unigestion is present and offers its services in the United States as Unigestion (US) Ltd, which is registered as an investment advisor with the U.S. Securities and Exchange Commission ("SEC"), which is registered as an investment advisor with the SEC. All inquiries from investors present in the United States should be directed to [clients@unigestion.com](mailto:clients@unigestion.com). This information is intended only for institutional clients that are qualified purchasers as defined by the SEC and has therefore not been adapted to retail clients.

#### **EUROPEAN UNION**

This material is disseminated in the European Union by Unigestion Asset Management (France) SA which is authorized and regulated by the French "Autorité des Marchés Financiers" ("AMF").

This information is intended only for professional clients and eligible counterparties, as defined in the MiFID directive and has therefore not been adapted to retail clients.

#### **CANADA**

This material is disseminated in Canada by Unigestion Asset Management (Canada) Inc. which is registered as a portfolio manager and/or exempt market dealer in nine provinces across Canada and also as an investment fund manager in Ontario, Quebec and Newfoundland & Labrador. Its principal regulator is the Ontario Securities Commission ("OSC"). This material may also be distributed by Unigestion SA which has an international advisor exemption in Quebec, Saskatchewan and Ontario. Unigestion SA's assets are situated outside of Canada and, as such, there may be difficulty enforcing legal rights against it.

#### **SWITZERLAND**

This material is disseminated in Switzerland by Unigestion SA which is authorized and regulated by the Swiss Financial Market Supervisory Authority ("FINMA").